Success Metrics

Clinical Success Rate
75.0%

Based on 15 completed trials

Completion Rate
75%(15/20)
Active Trials
1(4%)
Results Posted
80%(12 trials)
Terminated
5(18%)

Phase Distribution

Ph phase_2
7
25%
Ph phase_3
7
25%
Ph phase_4
2
7%
Ph not_applicable
2
7%
Ph phase_1
9
32%

Phase Distribution

9

Early Stage

7

Mid Stage

9

Late Stage

Phase Distribution27 total trials
Phase 1Safety & dosage
9(33.3%)
Phase 2Efficacy & side effects
7(25.9%)
Phase 3Large-scale testing
7(25.9%)
Phase 4Post-market surveillance
2(7.4%)
N/ANon-phased studies
2(7.4%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

65.2%

15 of 23 finished

Non-Completion Rate

34.8%

8 ended early

Currently Active

1

trials recruiting

Total Trials

28

all time

Status Distribution
Active(2)
Completed(15)
Terminated(8)
Other(3)

Detailed Status

Completed15
Terminated5
unknown3
Withdrawn3
Enrolling by invitation1
Recruiting1

Development Timeline

Analytics

Development Status

Total Trials
28
Active
1
Success Rate
75.0%
Most Advanced
Phase 4

Trials by Phase

Phase 19 (33.3%)
Phase 27 (25.9%)
Phase 37 (25.9%)
Phase 42 (7.4%)
N/A2 (7.4%)

Trials by Status

enrolling_by_invitation14%
unknown311%
withdrawn311%
terminated518%
completed1554%
recruiting14%

Recent Activity

Clinical Trials (28)

Showing 20 of 28 trialsScroll for more
NCT04977388Phase 1

NORTHERA (DROXIDOPA) for Dysautonomia in Adult Survivors of Menkes Disease and Occipital Horn Syndrome

Completed
NCT02897063Phase 1

Effects of Midodrine and Droxidopa on Splanchnic Capacitance in Autonomic Failure

Recruiting
NCT01370512Phase 2

Droxidopa / Pyridostigmine in Orthostatic Hypotension

Enrolling By Invitation
NCT01323374Phase 2

Study To Assess The Clinical Benefit Of Droxidopa And Droxidopa/Carbidopa In Subjects With Fibromyalgia

Completed
NCT01132326Phase 3

Clinical Study of Droxidopa in Patients With Neurogenic Orthostatic Hypotension (NOH) (Droxi-304)

Completed
NCT03229174Phase 4

Brain Perfusion & Oxygenation in Parkinson's Disease With NOH

Completed
NCT03446807Phase 2

Safety and Efficacy of Droxidopa for Fatigue in Patients With Parkinsonism

Withdrawn
NCT03115827Phase 4

Norepinephrine-targeted Therapy for Action Control in Parkinson Disease

Completed
NCT03567447Phase 2

Effect of L-Dihydroxyphenylserine (L-DOPS) on Falls in Patients With Neurogenic Orthostatic Hypotension (NOH)

Unknown
NCT03173781Not Applicable

Effects of Droxidopa When Measuring Gait Speed, Kyphosis, and Functional Reach in Parkinson's Disease

Completed
NCT03070730Phase 1

Hemodynamic Response of Neuropathic And Non-Neuropathic POTS Patients To Adrenoreceptor Agonist And Antagonist

Terminated
NCT02066571Phase 2

Study to Assess the Clinical Benefit and Safety of Droxidopa in Parkinson's Disease

Unknown
NCT00889135

Long Term Treatment With L-DOPS

Unknown
NCT01927055Phase 3

A Clinical Study of Patients With Symptomatic NOH to Assess Sustained Effects of Droxidopa Therapy

Terminated
NCT00547911Phase 1

Augmenting Effects of L-DOPS With Carbidopa and Entacapone

Terminated
NCT00657046Phase 2

Safety and Benefit Study of Droxidopa to Treat Patients With Intradialytic Hypotension

Completed
NCT00977171Phase 2

Study To Assess The Clinical Benefit Of Droxidopa In Subjects With Chronic Fatigue Syndrome

Terminated
NCT00633880Phase 3

Clinical Study of Droxidopa in Patients With Neurogenic Orthostatic Hypotension (NOH)

Completed
NCT01176240Phase 3

A Two Part Study (306A/306B) to Assess Droxidopa in Treatment of NOH in Patients With Parkinson's Disease

Completed
NCT00738062Phase 3

Open-Label Clinical Study of Droxidopa in Patients With Neurogenic Orthostatic Hypotension (NOH)

Completed

Drug Details

Intervention Type
DRUG
Total Trials
28